nodes	percent_of_prediction	percent_of_DWPC	metapath
Etoricoxib—CYP2E1—prostate cancer	0.102	0.309	CbGaD
Etoricoxib—CYP2C19—prostate cancer	0.101	0.306	CbGaD
Etoricoxib—CYP3A4—prostate cancer	0.0644	0.195	CbGaD
Etoricoxib—PTGS2—prostate cancer	0.063	0.19	CbGaD
Etoricoxib—CYP2C19—Bicalutamide—prostate cancer	0.0226	0.0592	CbGbCtD
Etoricoxib—CYP2C19—Nilutamide—prostate cancer	0.0226	0.0592	CbGbCtD
Etoricoxib—CYP2E1—Estrone—prostate cancer	0.0216	0.0566	CbGbCtD
Etoricoxib—CYP3A4—Estradiol valerate/Dienogest—prostate cancer	0.0208	0.0545	CbGbCtD
Etoricoxib—CYP2C9—Nilutamide—prostate cancer	0.0188	0.0492	CbGbCtD
Etoricoxib—CYP2C9—Bicalutamide—prostate cancer	0.0188	0.0492	CbGbCtD
Etoricoxib—CYP2C19—Flutamide—prostate cancer	0.0187	0.0491	CbGbCtD
Etoricoxib—CYP1A2—Flutamide—prostate cancer	0.0173	0.0453	CbGbCtD
Etoricoxib—CYP2D6—Bicalutamide—prostate cancer	0.0172	0.045	CbGbCtD
Etoricoxib—CYP2D6—Abiraterone—prostate cancer	0.0142	0.0373	CbGbCtD
Etoricoxib—CYP2E1—Mitoxantrone—prostate cancer	0.0129	0.0337	CbGbCtD
Etoricoxib—CYP1A2—Estrone—prostate cancer	0.0125	0.0327	CbGbCtD
Etoricoxib—PTGS2—Etoposide—prostate cancer	0.0124	0.0325	CbGbCtD
Etoricoxib—CYP2C9—Estrone—prostate cancer	0.0113	0.0295	CbGbCtD
Etoricoxib—CYP3A4—Bicalutamide—prostate cancer	0.0109	0.0286	CbGbCtD
Etoricoxib—CYP3A4—Estramustine—prostate cancer	0.0102	0.0266	CbGbCtD
Etoricoxib—CYP3A4—Abiraterone—prostate cancer	0.00906	0.0237	CbGbCtD
Etoricoxib—CYP3A4—Flutamide—prostate cancer	0.00906	0.0237	CbGbCtD
Etoricoxib—CYP2C9—Capecitabine—prostate cancer	0.00854	0.0224	CbGbCtD
Etoricoxib—CYP1A2—Conjugated Estrogens—prostate cancer	0.00818	0.0214	CbGbCtD
Etoricoxib—CYP2E1—Etoposide—prostate cancer	0.00811	0.0212	CbGbCtD
Etoricoxib—CYP2C19—Estradiol—prostate cancer	0.00778	0.0204	CbGbCtD
Etoricoxib—CYP1A2—Estradiol—prostate cancer	0.00718	0.0188	CbGbCtD
Etoricoxib—CYP3A4—Cabazitaxel—prostate cancer	0.0067	0.0175	CbGbCtD
Etoricoxib—CYP2C19—Prednisone—prostate cancer	0.00669	0.0175	CbGbCtD
Etoricoxib—CYP3A4—Estrone—prostate cancer	0.00655	0.0172	CbGbCtD
Etoricoxib—CYP2C9—Estradiol—prostate cancer	0.00647	0.0169	CbGbCtD
Etoricoxib—CYP3A4—Ethinyl Estradiol—prostate cancer	0.00584	0.0153	CbGbCtD
Etoricoxib—CYP1A2—Etoposide—prostate cancer	0.00469	0.0123	CbGbCtD
Etoricoxib—CYP3A4—Conjugated Estrogens—prostate cancer	0.00428	0.0112	CbGbCtD
Etoricoxib—CYP3A4—Mitoxantrone—prostate cancer	0.00389	0.0102	CbGbCtD
Etoricoxib—CYP3A4—Estradiol—prostate cancer	0.00376	0.00985	CbGbCtD
Etoricoxib—CYP3A4—Prednisone—prostate cancer	0.00323	0.00847	CbGbCtD
Etoricoxib—CYP2D6—Doxorubicin—prostate cancer	0.00263	0.0069	CbGbCtD
Etoricoxib—CYP3A4—Etoposide—prostate cancer	0.00246	0.00643	CbGbCtD
Etoricoxib—CYP2C19—urine—prostate cancer	0.00232	0.097	CbGeAlD
Etoricoxib—CYP3A4—Docetaxel—prostate cancer	0.00225	0.00589	CbGbCtD
Etoricoxib—MAPK14—prostate gland—prostate cancer	0.00196	0.0819	CbGeAlD
Etoricoxib—CYP1A2—urine—prostate cancer	0.0019	0.0792	CbGeAlD
Etoricoxib—CYP2C9—urine—prostate cancer	0.0018	0.0752	CbGeAlD
Etoricoxib—CYP2E1—urine—prostate cancer	0.00171	0.0712	CbGeAlD
Etoricoxib—CYP3A4—Doxorubicin—prostate cancer	0.00168	0.00439	CbGbCtD
Etoricoxib—MAPK14—epithelium—prostate cancer	0.00144	0.0602	CbGeAlD
Etoricoxib—CYP3A4—urine—prostate cancer	0.00137	0.0573	CbGeAlD
Etoricoxib—CYP2D6—urine—prostate cancer	0.00135	0.0564	CbGeAlD
Etoricoxib—MAPK14—renal system—prostate cancer	0.00134	0.0558	CbGeAlD
Etoricoxib—MAPK14—bone marrow—prostate cancer	0.00101	0.0422	CbGeAlD
Etoricoxib—MAPK14—testis—prostate cancer	0.000864	0.0361	CbGeAlD
Etoricoxib—MAPK14—lymph node—prostate cancer	0.000626	0.0261	CbGeAlD
Etoricoxib—CYP2E1—prostate gland—prostate cancer	0.000612	0.0256	CbGeAlD
Etoricoxib—PTGS2—prostate gland—prostate cancer	0.000564	0.0235	CbGeAlD
Etoricoxib—CYP2E1—seminal vesicle—prostate cancer	0.000518	0.0216	CbGeAlD
Etoricoxib—PTGS2—seminal vesicle—prostate cancer	0.000477	0.0199	CbGeAlD
Etoricoxib—CYP1A2—renal system—prostate cancer	0.000464	0.0194	CbGeAlD
Etoricoxib—Vemurafenib—CYP3A4—prostate cancer	0.000445	0.289	CrCbGaD
Etoricoxib—CYP2E1—renal system—prostate cancer	0.000417	0.0174	CbGeAlD
Etoricoxib—PTGS2—epithelium—prostate cancer	0.000414	0.0173	CbGeAlD
Etoricoxib—CYP2E1—urethra—prostate cancer	0.00041	0.0171	CbGeAlD
Etoricoxib—PTGS2—renal system—prostate cancer	0.000384	0.016	CbGeAlD
Etoricoxib—PTGS2—urethra—prostate cancer	0.000377	0.0158	CbGeAlD
Etoricoxib—Vismodegib—CYP2C19—prostate cancer	0.000353	0.229	CrCbGaD
Etoricoxib—CYP3A4—renal system—prostate cancer	0.000336	0.014	CbGeAlD
Etoricoxib—CYP2D6—renal system—prostate cancer	0.00033	0.0138	CbGeAlD
Etoricoxib—PTGS2—bone marrow—prostate cancer	0.000291	0.0121	CbGeAlD
Etoricoxib—CYP2E1—testis—prostate cancer	0.00027	0.0113	CbGeAlD
Etoricoxib—Celecoxib—CYP3A4—prostate cancer	0.000262	0.17	CrCbGaD
Etoricoxib—Celecoxib—PTGS2—prostate cancer	0.000256	0.166	CrCbGaD
Etoricoxib—Vismodegib—CYP3A4—prostate cancer	0.000224	0.146	CrCbGaD
Etoricoxib—CYP2D6—testis—prostate cancer	0.000214	0.00892	CbGeAlD
Etoricoxib—PTGS2—lymph node—prostate cancer	0.00018	0.00752	CbGeAlD
Etoricoxib—Neuropathy peripheral—Doxorubicin—prostate cancer	2.88e-05	0.000191	CcSEcCtD
Etoricoxib—Urticaria—Etoposide—prostate cancer	2.87e-05	0.00019	CcSEcCtD
Etoricoxib—Haemoglobin—Epirubicin—prostate cancer	2.87e-05	0.00019	CcSEcCtD
Etoricoxib—Jaundice—Doxorubicin—prostate cancer	2.87e-05	0.000189	CcSEcCtD
Etoricoxib—Stomatitis—Doxorubicin—prostate cancer	2.87e-05	0.000189	CcSEcCtD
Etoricoxib—Anorexia—Docetaxel—prostate cancer	2.87e-05	0.000189	CcSEcCtD
Etoricoxib—Shock—Capecitabine—prostate cancer	2.86e-05	0.000189	CcSEcCtD
Etoricoxib—Abdominal pain—Etoposide—prostate cancer	2.86e-05	0.000189	CcSEcCtD
Etoricoxib—Urinary tract infection—Doxorubicin—prostate cancer	2.86e-05	0.000189	CcSEcCtD
Etoricoxib—Conjunctivitis—Doxorubicin—prostate cancer	2.86e-05	0.000189	CcSEcCtD
Etoricoxib—Nervous system disorder—Capecitabine—prostate cancer	2.86e-05	0.000189	CcSEcCtD
Etoricoxib—Haemorrhage—Epirubicin—prostate cancer	2.85e-05	0.000189	CcSEcCtD
Etoricoxib—Hepatitis—Epirubicin—prostate cancer	2.85e-05	0.000189	CcSEcCtD
Etoricoxib—Thrombocytopenia—Capecitabine—prostate cancer	2.85e-05	0.000188	CcSEcCtD
Etoricoxib—Hypoaesthesia—Epirubicin—prostate cancer	2.84e-05	0.000188	CcSEcCtD
Etoricoxib—Pharyngitis—Epirubicin—prostate cancer	2.83e-05	0.000187	CcSEcCtD
Etoricoxib—Skin disorder—Capecitabine—prostate cancer	2.83e-05	0.000187	CcSEcCtD
Etoricoxib—Urinary tract disorder—Epirubicin—prostate cancer	2.82e-05	0.000186	CcSEcCtD
Etoricoxib—Oedema peripheral—Epirubicin—prostate cancer	2.81e-05	0.000186	CcSEcCtD
Etoricoxib—Haematuria—Doxorubicin—prostate cancer	2.81e-05	0.000185	CcSEcCtD
Etoricoxib—Connective tissue disorder—Epirubicin—prostate cancer	2.81e-05	0.000185	CcSEcCtD
Etoricoxib—Urethral disorder—Epirubicin—prostate cancer	2.8e-05	0.000185	CcSEcCtD
Etoricoxib—Hepatobiliary disease—Doxorubicin—prostate cancer	2.78e-05	0.000184	CcSEcCtD
Etoricoxib—Epistaxis—Doxorubicin—prostate cancer	2.78e-05	0.000183	CcSEcCtD
Etoricoxib—Anorexia—Capecitabine—prostate cancer	2.78e-05	0.000183	CcSEcCtD
Etoricoxib—Nausea—Estradiol—prostate cancer	2.77e-05	0.000183	CcSEcCtD
Etoricoxib—Vomiting—Mitoxantrone—prostate cancer	2.77e-05	0.000183	CcSEcCtD
Etoricoxib—Sinusitis—Doxorubicin—prostate cancer	2.76e-05	0.000182	CcSEcCtD
Etoricoxib—Visual impairment—Epirubicin—prostate cancer	2.75e-05	0.000182	CcSEcCtD
Etoricoxib—Hypertension—Prednisone—prostate cancer	2.74e-05	0.000181	CcSEcCtD
Etoricoxib—Rash—Mitoxantrone—prostate cancer	2.74e-05	0.000181	CcSEcCtD
Etoricoxib—Dermatitis—Mitoxantrone—prostate cancer	2.74e-05	0.000181	CcSEcCtD
Etoricoxib—Musculoskeletal discomfort—Docetaxel—prostate cancer	2.74e-05	0.000181	CcSEcCtD
Etoricoxib—Headache—Mitoxantrone—prostate cancer	2.73e-05	0.00018	CcSEcCtD
Etoricoxib—Insomnia—Docetaxel—prostate cancer	2.72e-05	0.00018	CcSEcCtD
Etoricoxib—Arthralgia—Prednisone—prostate cancer	2.71e-05	0.000179	CcSEcCtD
Etoricoxib—Erythema multiforme—Epirubicin—prostate cancer	2.7e-05	0.000178	CcSEcCtD
Etoricoxib—Anxiety—Prednisone—prostate cancer	2.7e-05	0.000178	CcSEcCtD
Etoricoxib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—prostate cancer	2.69e-05	0.000177	CcSEcCtD
Etoricoxib—Dyspnoea—Docetaxel—prostate cancer	2.68e-05	0.000177	CcSEcCtD
Etoricoxib—Somnolence—Docetaxel—prostate cancer	2.67e-05	0.000177	CcSEcCtD
Etoricoxib—Eye disorder—Epirubicin—prostate cancer	2.67e-05	0.000176	CcSEcCtD
Etoricoxib—Hypersensitivity—Etoposide—prostate cancer	2.67e-05	0.000176	CcSEcCtD
Etoricoxib—Tinnitus—Epirubicin—prostate cancer	2.66e-05	0.000176	CcSEcCtD
Etoricoxib—Haemoglobin—Doxorubicin—prostate cancer	2.65e-05	0.000175	CcSEcCtD
Etoricoxib—Musculoskeletal discomfort—Capecitabine—prostate cancer	2.65e-05	0.000175	CcSEcCtD
Etoricoxib—Flushing—Epirubicin—prostate cancer	2.65e-05	0.000175	CcSEcCtD
Etoricoxib—Cardiac disorder—Epirubicin—prostate cancer	2.65e-05	0.000175	CcSEcCtD
Etoricoxib—Dyspepsia—Docetaxel—prostate cancer	2.65e-05	0.000175	CcSEcCtD
Etoricoxib—Haemorrhage—Doxorubicin—prostate cancer	2.64e-05	0.000175	CcSEcCtD
Etoricoxib—Hepatitis—Doxorubicin—prostate cancer	2.64e-05	0.000175	CcSEcCtD
Etoricoxib—Insomnia—Capecitabine—prostate cancer	2.63e-05	0.000174	CcSEcCtD
Etoricoxib—Hypoaesthesia—Doxorubicin—prostate cancer	2.63e-05	0.000174	CcSEcCtD
Etoricoxib—Pharyngitis—Doxorubicin—prostate cancer	2.62e-05	0.000173	CcSEcCtD
Etoricoxib—Decreased appetite—Docetaxel—prostate cancer	2.61e-05	0.000173	CcSEcCtD
Etoricoxib—Urinary tract disorder—Doxorubicin—prostate cancer	2.61e-05	0.000172	CcSEcCtD
Etoricoxib—Oedema peripheral—Doxorubicin—prostate cancer	2.6e-05	0.000172	CcSEcCtD
Etoricoxib—Gastrointestinal disorder—Docetaxel—prostate cancer	2.6e-05	0.000172	CcSEcCtD
Etoricoxib—Asthenia—Etoposide—prostate cancer	2.6e-05	0.000172	CcSEcCtD
Etoricoxib—Connective tissue disorder—Doxorubicin—prostate cancer	2.6e-05	0.000171	CcSEcCtD
Etoricoxib—Dyspnoea—Capecitabine—prostate cancer	2.6e-05	0.000171	CcSEcCtD
Etoricoxib—Oedema—Prednisone—prostate cancer	2.59e-05	0.000171	CcSEcCtD
Etoricoxib—Anaphylactic shock—Prednisone—prostate cancer	2.59e-05	0.000171	CcSEcCtD
Etoricoxib—Fatigue—Docetaxel—prostate cancer	2.59e-05	0.000171	CcSEcCtD
Etoricoxib—Angiopathy—Epirubicin—prostate cancer	2.59e-05	0.000171	CcSEcCtD
Etoricoxib—Urethral disorder—Doxorubicin—prostate cancer	2.59e-05	0.000171	CcSEcCtD
Etoricoxib—Nausea—Mitoxantrone—prostate cancer	2.58e-05	0.000171	CcSEcCtD
Etoricoxib—Immune system disorder—Epirubicin—prostate cancer	2.58e-05	0.00017	CcSEcCtD
Etoricoxib—Infection—Prednisone—prostate cancer	2.58e-05	0.00017	CcSEcCtD
Etoricoxib—Mediastinal disorder—Epirubicin—prostate cancer	2.57e-05	0.00017	CcSEcCtD
Etoricoxib—Pain—Docetaxel—prostate cancer	2.57e-05	0.00017	CcSEcCtD
Etoricoxib—Constipation—Docetaxel—prostate cancer	2.57e-05	0.00017	CcSEcCtD
Etoricoxib—Dyspepsia—Capecitabine—prostate cancer	2.56e-05	0.000169	CcSEcCtD
Etoricoxib—Pruritus—Etoposide—prostate cancer	2.56e-05	0.000169	CcSEcCtD
Etoricoxib—Shock—Prednisone—prostate cancer	2.55e-05	0.000169	CcSEcCtD
Etoricoxib—Arrhythmia—Epirubicin—prostate cancer	2.55e-05	0.000168	CcSEcCtD
Etoricoxib—Visual impairment—Doxorubicin—prostate cancer	2.55e-05	0.000168	CcSEcCtD
Etoricoxib—Nervous system disorder—Prednisone—prostate cancer	2.54e-05	0.000168	CcSEcCtD
Etoricoxib—Decreased appetite—Capecitabine—prostate cancer	2.53e-05	0.000167	CcSEcCtD
Etoricoxib—Alopecia—Epirubicin—prostate cancer	2.52e-05	0.000167	CcSEcCtD
Etoricoxib—Skin disorder—Prednisone—prostate cancer	2.52e-05	0.000166	CcSEcCtD
Etoricoxib—Gastrointestinal disorder—Capecitabine—prostate cancer	2.51e-05	0.000166	CcSEcCtD
Etoricoxib—Fatigue—Capecitabine—prostate cancer	2.51e-05	0.000166	CcSEcCtD
Etoricoxib—Mental disorder—Epirubicin—prostate cancer	2.5e-05	0.000165	CcSEcCtD
Etoricoxib—Erythema multiforme—Doxorubicin—prostate cancer	2.5e-05	0.000165	CcSEcCtD
Etoricoxib—Pain—Capecitabine—prostate cancer	2.49e-05	0.000164	CcSEcCtD
Etoricoxib—Constipation—Capecitabine—prostate cancer	2.49e-05	0.000164	CcSEcCtD
Etoricoxib—Malnutrition—Epirubicin—prostate cancer	2.49e-05	0.000164	CcSEcCtD
Etoricoxib—Erythema—Epirubicin—prostate cancer	2.49e-05	0.000164	CcSEcCtD
Etoricoxib—Feeling abnormal—Docetaxel—prostate cancer	2.48e-05	0.000164	CcSEcCtD
Etoricoxib—Diarrhoea—Etoposide—prostate cancer	2.48e-05	0.000164	CcSEcCtD
Etoricoxib—Anorexia—Prednisone—prostate cancer	2.47e-05	0.000163	CcSEcCtD
Etoricoxib—Eye disorder—Doxorubicin—prostate cancer	2.47e-05	0.000163	CcSEcCtD
Etoricoxib—Tinnitus—Doxorubicin—prostate cancer	2.46e-05	0.000163	CcSEcCtD
Etoricoxib—Gastrointestinal pain—Docetaxel—prostate cancer	2.46e-05	0.000162	CcSEcCtD
Etoricoxib—Cardiac disorder—Doxorubicin—prostate cancer	2.45e-05	0.000162	CcSEcCtD
Etoricoxib—Flushing—Doxorubicin—prostate cancer	2.45e-05	0.000162	CcSEcCtD
Etoricoxib—Flatulence—Epirubicin—prostate cancer	2.45e-05	0.000162	CcSEcCtD
Etoricoxib—Dysgeusia—Epirubicin—prostate cancer	2.43e-05	0.000161	CcSEcCtD
Etoricoxib—Feeling abnormal—Capecitabine—prostate cancer	2.4e-05	0.000159	CcSEcCtD
Etoricoxib—Angiopathy—Doxorubicin—prostate cancer	2.4e-05	0.000158	CcSEcCtD
Etoricoxib—Dizziness—Etoposide—prostate cancer	2.39e-05	0.000158	CcSEcCtD
Etoricoxib—Muscle spasms—Epirubicin—prostate cancer	2.39e-05	0.000158	CcSEcCtD
Etoricoxib—Immune system disorder—Doxorubicin—prostate cancer	2.39e-05	0.000158	CcSEcCtD
Etoricoxib—Gastrointestinal pain—Capecitabine—prostate cancer	2.38e-05	0.000157	CcSEcCtD
Etoricoxib—Mediastinal disorder—Doxorubicin—prostate cancer	2.38e-05	0.000157	CcSEcCtD
Etoricoxib—Abdominal pain—Docetaxel—prostate cancer	2.38e-05	0.000157	CcSEcCtD
Etoricoxib—Musculoskeletal discomfort—Prednisone—prostate cancer	2.36e-05	0.000156	CcSEcCtD
Etoricoxib—Arrhythmia—Doxorubicin—prostate cancer	2.36e-05	0.000156	CcSEcCtD
Etoricoxib—Insomnia—Prednisone—prostate cancer	2.35e-05	0.000155	CcSEcCtD
Etoricoxib—Vision blurred—Epirubicin—prostate cancer	2.34e-05	0.000155	CcSEcCtD
Etoricoxib—Alopecia—Doxorubicin—prostate cancer	2.33e-05	0.000154	CcSEcCtD
Etoricoxib—Mental disorder—Doxorubicin—prostate cancer	2.31e-05	0.000153	CcSEcCtD
Etoricoxib—Urticaria—Capecitabine—prostate cancer	2.31e-05	0.000153	CcSEcCtD
Etoricoxib—Abdominal pain—Capecitabine—prostate cancer	2.3e-05	0.000152	CcSEcCtD
Etoricoxib—Vomiting—Etoposide—prostate cancer	2.3e-05	0.000152	CcSEcCtD
Etoricoxib—Erythema—Doxorubicin—prostate cancer	2.3e-05	0.000152	CcSEcCtD
Etoricoxib—Malnutrition—Doxorubicin—prostate cancer	2.3e-05	0.000152	CcSEcCtD
Etoricoxib—Anaemia—Epirubicin—prostate cancer	2.3e-05	0.000152	CcSEcCtD
Etoricoxib—Agitation—Epirubicin—prostate cancer	2.28e-05	0.000151	CcSEcCtD
Etoricoxib—Dyspepsia—Prednisone—prostate cancer	2.28e-05	0.000151	CcSEcCtD
Etoricoxib—Rash—Etoposide—prostate cancer	2.28e-05	0.000151	CcSEcCtD
Etoricoxib—Dermatitis—Etoposide—prostate cancer	2.28e-05	0.000151	CcSEcCtD
Etoricoxib—Headache—Etoposide—prostate cancer	2.27e-05	0.00015	CcSEcCtD
Etoricoxib—Flatulence—Doxorubicin—prostate cancer	2.27e-05	0.00015	CcSEcCtD
Etoricoxib—Decreased appetite—Prednisone—prostate cancer	2.25e-05	0.000149	CcSEcCtD
Etoricoxib—Dysgeusia—Doxorubicin—prostate cancer	2.25e-05	0.000149	CcSEcCtD
Etoricoxib—Fatigue—Prednisone—prostate cancer	2.24e-05	0.000148	CcSEcCtD
Etoricoxib—Constipation—Prednisone—prostate cancer	2.22e-05	0.000147	CcSEcCtD
Etoricoxib—Hypersensitivity—Docetaxel—prostate cancer	2.22e-05	0.000146	CcSEcCtD
Etoricoxib—Muscle spasms—Doxorubicin—prostate cancer	2.21e-05	0.000146	CcSEcCtD
Etoricoxib—Palpitations—Epirubicin—prostate cancer	2.2e-05	0.000145	CcSEcCtD
Etoricoxib—Cough—Epirubicin—prostate cancer	2.17e-05	0.000143	CcSEcCtD
Etoricoxib—Vision blurred—Doxorubicin—prostate cancer	2.17e-05	0.000143	CcSEcCtD
Etoricoxib—Asthenia—Docetaxel—prostate cancer	2.16e-05	0.000143	CcSEcCtD
Etoricoxib—Nausea—Etoposide—prostate cancer	2.15e-05	0.000142	CcSEcCtD
Etoricoxib—Hypertension—Epirubicin—prostate cancer	2.15e-05	0.000142	CcSEcCtD
Etoricoxib—Hypersensitivity—Capecitabine—prostate cancer	2.14e-05	0.000142	CcSEcCtD
Etoricoxib—Feeling abnormal—Prednisone—prostate cancer	2.14e-05	0.000141	CcSEcCtD
Etoricoxib—Pruritus—Docetaxel—prostate cancer	2.13e-05	0.000141	CcSEcCtD
Etoricoxib—Anaemia—Doxorubicin—prostate cancer	2.13e-05	0.00014	CcSEcCtD
Etoricoxib—Gastrointestinal pain—Prednisone—prostate cancer	2.12e-05	0.00014	CcSEcCtD
Etoricoxib—Arthralgia—Epirubicin—prostate cancer	2.12e-05	0.00014	CcSEcCtD
Etoricoxib—Chest pain—Epirubicin—prostate cancer	2.12e-05	0.00014	CcSEcCtD
Etoricoxib—Agitation—Doxorubicin—prostate cancer	2.11e-05	0.00014	CcSEcCtD
Etoricoxib—Anxiety—Epirubicin—prostate cancer	2.11e-05	0.000139	CcSEcCtD
Etoricoxib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—prostate cancer	2.1e-05	0.000139	CcSEcCtD
Etoricoxib—Asthenia—Capecitabine—prostate cancer	2.09e-05	0.000138	CcSEcCtD
Etoricoxib—Dry mouth—Epirubicin—prostate cancer	2.07e-05	0.000137	CcSEcCtD
Etoricoxib—Urticaria—Prednisone—prostate cancer	2.06e-05	0.000136	CcSEcCtD
Etoricoxib—Pruritus—Capecitabine—prostate cancer	2.06e-05	0.000136	CcSEcCtD
Etoricoxib—Diarrhoea—Docetaxel—prostate cancer	2.06e-05	0.000136	CcSEcCtD
Etoricoxib—Abdominal pain—Prednisone—prostate cancer	2.05e-05	0.000135	CcSEcCtD
Etoricoxib—Confusional state—Epirubicin—prostate cancer	2.05e-05	0.000135	CcSEcCtD
Etoricoxib—Palpitations—Doxorubicin—prostate cancer	2.03e-05	0.000134	CcSEcCtD
Etoricoxib—Anaphylactic shock—Epirubicin—prostate cancer	2.03e-05	0.000134	CcSEcCtD
Etoricoxib—Oedema—Epirubicin—prostate cancer	2.03e-05	0.000134	CcSEcCtD
Etoricoxib—Infection—Epirubicin—prostate cancer	2.01e-05	0.000133	CcSEcCtD
Etoricoxib—Cough—Doxorubicin—prostate cancer	2.01e-05	0.000133	CcSEcCtD
Etoricoxib—Shock—Epirubicin—prostate cancer	2e-05	0.000132	CcSEcCtD
Etoricoxib—Diarrhoea—Capecitabine—prostate cancer	1.99e-05	0.000132	CcSEcCtD
Etoricoxib—Nervous system disorder—Epirubicin—prostate cancer	1.99e-05	0.000131	CcSEcCtD
Etoricoxib—Dizziness—Docetaxel—prostate cancer	1.99e-05	0.000131	CcSEcCtD
Etoricoxib—Thrombocytopenia—Epirubicin—prostate cancer	1.99e-05	0.000131	CcSEcCtD
Etoricoxib—Hypertension—Doxorubicin—prostate cancer	1.99e-05	0.000131	CcSEcCtD
Etoricoxib—Skin disorder—Epirubicin—prostate cancer	1.97e-05	0.00013	CcSEcCtD
Etoricoxib—Arthralgia—Doxorubicin—prostate cancer	1.96e-05	0.000129	CcSEcCtD
Etoricoxib—Chest pain—Doxorubicin—prostate cancer	1.96e-05	0.000129	CcSEcCtD
Etoricoxib—Anxiety—Doxorubicin—prostate cancer	1.95e-05	0.000129	CcSEcCtD
Etoricoxib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—prostate cancer	1.94e-05	0.000128	CcSEcCtD
Etoricoxib—Anorexia—Epirubicin—prostate cancer	1.93e-05	0.000128	CcSEcCtD
Etoricoxib—Dizziness—Capecitabine—prostate cancer	1.93e-05	0.000127	CcSEcCtD
Etoricoxib—Dry mouth—Doxorubicin—prostate cancer	1.91e-05	0.000126	CcSEcCtD
Etoricoxib—Vomiting—Docetaxel—prostate cancer	1.91e-05	0.000126	CcSEcCtD
Etoricoxib—Hypersensitivity—Prednisone—prostate cancer	1.91e-05	0.000126	CcSEcCtD
Etoricoxib—Rash—Docetaxel—prostate cancer	1.9e-05	0.000125	CcSEcCtD
Etoricoxib—Dermatitis—Docetaxel—prostate cancer	1.89e-05	0.000125	CcSEcCtD
Etoricoxib—Confusional state—Doxorubicin—prostate cancer	1.89e-05	0.000125	CcSEcCtD
Etoricoxib—Headache—Docetaxel—prostate cancer	1.88e-05	0.000124	CcSEcCtD
Etoricoxib—Anaphylactic shock—Doxorubicin—prostate cancer	1.88e-05	0.000124	CcSEcCtD
Etoricoxib—Oedema—Doxorubicin—prostate cancer	1.88e-05	0.000124	CcSEcCtD
Etoricoxib—Infection—Doxorubicin—prostate cancer	1.86e-05	0.000123	CcSEcCtD
Etoricoxib—Asthenia—Prednisone—prostate cancer	1.86e-05	0.000123	CcSEcCtD
Etoricoxib—Vomiting—Capecitabine—prostate cancer	1.85e-05	0.000122	CcSEcCtD
Etoricoxib—Musculoskeletal discomfort—Epirubicin—prostate cancer	1.85e-05	0.000122	CcSEcCtD
Etoricoxib—Shock—Doxorubicin—prostate cancer	1.85e-05	0.000122	CcSEcCtD
Etoricoxib—Nervous system disorder—Doxorubicin—prostate cancer	1.84e-05	0.000122	CcSEcCtD
Etoricoxib—Thrombocytopenia—Doxorubicin—prostate cancer	1.84e-05	0.000121	CcSEcCtD
Etoricoxib—Rash—Capecitabine—prostate cancer	1.84e-05	0.000121	CcSEcCtD
Etoricoxib—Pruritus—Prednisone—prostate cancer	1.83e-05	0.000121	CcSEcCtD
Etoricoxib—Insomnia—Epirubicin—prostate cancer	1.83e-05	0.000121	CcSEcCtD
Etoricoxib—Dermatitis—Capecitabine—prostate cancer	1.83e-05	0.000121	CcSEcCtD
Etoricoxib—Headache—Capecitabine—prostate cancer	1.82e-05	0.00012	CcSEcCtD
Etoricoxib—Skin disorder—Doxorubicin—prostate cancer	1.82e-05	0.00012	CcSEcCtD
Etoricoxib—Dyspnoea—Epirubicin—prostate cancer	1.81e-05	0.000119	CcSEcCtD
Etoricoxib—Somnolence—Epirubicin—prostate cancer	1.8e-05	0.000119	CcSEcCtD
Etoricoxib—Anorexia—Doxorubicin—prostate cancer	1.79e-05	0.000118	CcSEcCtD
Etoricoxib—Nausea—Docetaxel—prostate cancer	1.79e-05	0.000118	CcSEcCtD
Etoricoxib—Dyspepsia—Epirubicin—prostate cancer	1.79e-05	0.000118	CcSEcCtD
Etoricoxib—Diarrhoea—Prednisone—prostate cancer	1.77e-05	0.000117	CcSEcCtD
Etoricoxib—Decreased appetite—Epirubicin—prostate cancer	1.76e-05	0.000116	CcSEcCtD
Etoricoxib—Gastrointestinal disorder—Epirubicin—prostate cancer	1.75e-05	0.000116	CcSEcCtD
Etoricoxib—Fatigue—Epirubicin—prostate cancer	1.75e-05	0.000116	CcSEcCtD
Etoricoxib—Constipation—Epirubicin—prostate cancer	1.73e-05	0.000115	CcSEcCtD
Etoricoxib—Pain—Epirubicin—prostate cancer	1.73e-05	0.000115	CcSEcCtD
Etoricoxib—Nausea—Capecitabine—prostate cancer	1.73e-05	0.000114	CcSEcCtD
Etoricoxib—Dizziness—Prednisone—prostate cancer	1.71e-05	0.000113	CcSEcCtD
Etoricoxib—Musculoskeletal discomfort—Doxorubicin—prostate cancer	1.71e-05	0.000113	CcSEcCtD
Etoricoxib—Insomnia—Doxorubicin—prostate cancer	1.7e-05	0.000112	CcSEcCtD
Etoricoxib—Dyspnoea—Doxorubicin—prostate cancer	1.67e-05	0.000111	CcSEcCtD
Etoricoxib—Feeling abnormal—Epirubicin—prostate cancer	1.67e-05	0.00011	CcSEcCtD
Etoricoxib—Somnolence—Doxorubicin—prostate cancer	1.67e-05	0.00011	CcSEcCtD
Etoricoxib—Gastrointestinal pain—Epirubicin—prostate cancer	1.66e-05	0.00011	CcSEcCtD
Etoricoxib—Dyspepsia—Doxorubicin—prostate cancer	1.65e-05	0.000109	CcSEcCtD
Etoricoxib—Vomiting—Prednisone—prostate cancer	1.65e-05	0.000109	CcSEcCtD
Etoricoxib—Rash—Prednisone—prostate cancer	1.64e-05	0.000108	CcSEcCtD
Etoricoxib—Dermatitis—Prednisone—prostate cancer	1.63e-05	0.000108	CcSEcCtD
Etoricoxib—Decreased appetite—Doxorubicin—prostate cancer	1.63e-05	0.000108	CcSEcCtD
Etoricoxib—Headache—Prednisone—prostate cancer	1.62e-05	0.000107	CcSEcCtD
Etoricoxib—Gastrointestinal disorder—Doxorubicin—prostate cancer	1.62e-05	0.000107	CcSEcCtD
Etoricoxib—Fatigue—Doxorubicin—prostate cancer	1.62e-05	0.000107	CcSEcCtD
Etoricoxib—Urticaria—Epirubicin—prostate cancer	1.61e-05	0.000106	CcSEcCtD
Etoricoxib—Pain—Doxorubicin—prostate cancer	1.6e-05	0.000106	CcSEcCtD
Etoricoxib—Constipation—Doxorubicin—prostate cancer	1.6e-05	0.000106	CcSEcCtD
Etoricoxib—Abdominal pain—Epirubicin—prostate cancer	1.6e-05	0.000106	CcSEcCtD
Etoricoxib—Feeling abnormal—Doxorubicin—prostate cancer	1.55e-05	0.000102	CcSEcCtD
Etoricoxib—Nausea—Prednisone—prostate cancer	1.54e-05	0.000102	CcSEcCtD
Etoricoxib—Gastrointestinal pain—Doxorubicin—prostate cancer	1.53e-05	0.000101	CcSEcCtD
Etoricoxib—Hypersensitivity—Epirubicin—prostate cancer	1.49e-05	9.87e-05	CcSEcCtD
Etoricoxib—Urticaria—Doxorubicin—prostate cancer	1.49e-05	9.85e-05	CcSEcCtD
Etoricoxib—Abdominal pain—Doxorubicin—prostate cancer	1.48e-05	9.8e-05	CcSEcCtD
Etoricoxib—Asthenia—Epirubicin—prostate cancer	1.46e-05	9.61e-05	CcSEcCtD
Etoricoxib—Pruritus—Epirubicin—prostate cancer	1.43e-05	9.48e-05	CcSEcCtD
Etoricoxib—Diarrhoea—Epirubicin—prostate cancer	1.39e-05	9.17e-05	CcSEcCtD
Etoricoxib—Hypersensitivity—Doxorubicin—prostate cancer	1.38e-05	9.13e-05	CcSEcCtD
Etoricoxib—Asthenia—Doxorubicin—prostate cancer	1.35e-05	8.9e-05	CcSEcCtD
Etoricoxib—Dizziness—Epirubicin—prostate cancer	1.34e-05	8.86e-05	CcSEcCtD
Etoricoxib—Pruritus—Doxorubicin—prostate cancer	1.33e-05	8.77e-05	CcSEcCtD
Etoricoxib—Vomiting—Epirubicin—prostate cancer	1.29e-05	8.52e-05	CcSEcCtD
Etoricoxib—Diarrhoea—Doxorubicin—prostate cancer	1.28e-05	8.48e-05	CcSEcCtD
Etoricoxib—Rash—Epirubicin—prostate cancer	1.28e-05	8.45e-05	CcSEcCtD
Etoricoxib—Dermatitis—Epirubicin—prostate cancer	1.28e-05	8.44e-05	CcSEcCtD
Etoricoxib—Headache—Epirubicin—prostate cancer	1.27e-05	8.39e-05	CcSEcCtD
Etoricoxib—Dizziness—Doxorubicin—prostate cancer	1.24e-05	8.2e-05	CcSEcCtD
Etoricoxib—Nausea—Epirubicin—prostate cancer	1.2e-05	7.96e-05	CcSEcCtD
Etoricoxib—Vomiting—Doxorubicin—prostate cancer	1.19e-05	7.88e-05	CcSEcCtD
Etoricoxib—Rash—Doxorubicin—prostate cancer	1.18e-05	7.82e-05	CcSEcCtD
Etoricoxib—Dermatitis—Doxorubicin—prostate cancer	1.18e-05	7.81e-05	CcSEcCtD
Etoricoxib—Headache—Doxorubicin—prostate cancer	1.18e-05	7.77e-05	CcSEcCtD
Etoricoxib—Nausea—Doxorubicin—prostate cancer	1.11e-05	7.36e-05	CcSEcCtD
Etoricoxib—CYP3A4—Metabolism—P4HB—prostate cancer	2.09e-06	1.89e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—prostate cancer	2.08e-06	1.88e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—CYP1B1—prostate cancer	2.08e-06	1.88e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—RXRA—prostate cancer	2.07e-06	1.87e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Gene Expression—MYC—prostate cancer	2.07e-06	1.87e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—CREBBP—prostate cancer	2.06e-06	1.87e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—FGF2—prostate cancer	2.05e-06	1.86e-05	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—PPARA—prostate cancer	2.05e-06	1.85e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—CAV1—prostate cancer	2.05e-06	1.85e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—GGT1—prostate cancer	2.03e-06	1.84e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—EGFR—prostate cancer	2.03e-06	1.84e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—SLC22A1—prostate cancer	2.03e-06	1.84e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—NOS3—prostate cancer	2.03e-06	1.83e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—GGT1—prostate cancer	2.01e-06	1.82e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—prostate cancer	2.01e-06	1.82e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—NCOA2—prostate cancer	2.01e-06	1.82e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—NCOA1—prostate cancer	2e-06	1.81e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—COMT—prostate cancer	1.99e-06	1.8e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—GSTP1—prostate cancer	1.98e-06	1.79e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—NCOA1—prostate cancer	1.98e-06	1.79e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—SULT2A1—prostate cancer	1.98e-06	1.79e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—CYP19A1—prostate cancer	1.97e-06	1.78e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—MAP2K1—prostate cancer	1.97e-06	1.78e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—JAK2—prostate cancer	1.97e-06	1.78e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—PIK3CD—prostate cancer	1.96e-06	1.77e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—CYP19A1—prostate cancer	1.96e-06	1.77e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	1.96e-06	1.77e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—ITPR1—prostate cancer	1.95e-06	1.76e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—MED12—prostate cancer	1.95e-06	1.76e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—SERPINE1—prostate cancer	1.94e-06	1.75e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—GNG5—prostate cancer	1.93e-06	1.75e-05	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—CAV1—prostate cancer	1.93e-06	1.74e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—MDM2—prostate cancer	1.92e-06	1.74e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism of lipids and lipoproteins—EP300—prostate cancer	1.92e-06	1.74e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—SLC5A5—prostate cancer	1.92e-06	1.73e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—KRAS—prostate cancer	1.92e-06	1.73e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—RXRA—prostate cancer	1.9e-06	1.72e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—ERBB2—prostate cancer	1.89e-06	1.71e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—RXRA—prostate cancer	1.89e-06	1.71e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—CYP2E1—prostate cancer	1.87e-06	1.69e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—FGF2—prostate cancer	1.87e-06	1.69e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—PIK3CB—prostate cancer	1.87e-06	1.69e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—PIK3CG—prostate cancer	1.86e-06	1.69e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—NCOA3—prostate cancer	1.86e-06	1.68e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—NQO1—prostate cancer	1.85e-06	1.68e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—NOS3—prostate cancer	1.85e-06	1.67e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—TYMS—prostate cancer	1.84e-06	1.67e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—prostate cancer	1.84e-06	1.66e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—COMT—prostate cancer	1.83e-06	1.66e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—TH—prostate cancer	1.83e-06	1.65e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—GSTP1—prostate cancer	1.83e-06	1.65e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—GSTM1—prostate cancer	1.82e-06	1.65e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—COMT—prostate cancer	1.82e-06	1.64e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—prostate cancer	1.82e-06	1.64e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—GSTP1—prostate cancer	1.81e-06	1.64e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—CYP3A4—prostate cancer	1.81e-06	1.63e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—prostate cancer	1.8e-06	1.63e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—CXCL8—prostate cancer	1.8e-06	1.62e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—JAK2—prostate cancer	1.8e-06	1.62e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—ITPR1—prostate cancer	1.8e-06	1.62e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—LPL—prostate cancer	1.79e-06	1.62e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—ITPR1—prostate cancer	1.78e-06	1.61e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—CYP1B1—prostate cancer	1.78e-06	1.61e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—HPGDS—prostate cancer	1.77e-06	1.6e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—INS—prostate cancer	1.76e-06	1.6e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—CYP2C19—prostate cancer	1.76e-06	1.59e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—PIK3CA—prostate cancer	1.76e-06	1.59e-05	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—PIK3CG—prostate cancer	1.76e-06	1.59e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—CDKN1B—prostate cancer	1.75e-06	1.59e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—MDM2—prostate cancer	1.75e-06	1.58e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism of lipids and lipoproteins—EP300—prostate cancer	1.75e-06	1.58e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—CYP1A1—prostate cancer	1.73e-06	1.56e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—CREBBP—prostate cancer	1.73e-06	1.56e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—ERBB2—prostate cancer	1.73e-06	1.56e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—GSTT1—prostate cancer	1.72e-06	1.56e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—ACHE—prostate cancer	1.72e-06	1.56e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—GGT1—prostate cancer	1.72e-06	1.56e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—CASP3—prostate cancer	1.72e-06	1.55e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—IL2—prostate cancer	1.72e-06	1.55e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—ERCC2—prostate cancer	1.71e-06	1.55e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—PIK3CB—prostate cancer	1.71e-06	1.54e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—CYP2A6—prostate cancer	1.7e-06	1.54e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—TYMS—prostate cancer	1.7e-06	1.53e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—NCOA1—prostate cancer	1.7e-06	1.53e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—TYMS—prostate cancer	1.68e-06	1.52e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—GSTM1—prostate cancer	1.68e-06	1.52e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—CCND1—prostate cancer	1.67e-06	1.51e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—CYP19A1—prostate cancer	1.67e-06	1.51e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—GSTM1—prostate cancer	1.66e-06	1.5e-05	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—INS—prostate cancer	1.66e-06	1.5e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—CTNNB1—prostate cancer	1.66e-06	1.5e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—AKR1C3—prostate cancer	1.66e-06	1.5e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—PRKACB—prostate cancer	1.65e-06	1.49e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—LPL—prostate cancer	1.65e-06	1.49e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—PIK3CD—prostate cancer	1.64e-06	1.48e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—LPL—prostate cancer	1.63e-06	1.48e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—CYP17A1—prostate cancer	1.63e-06	1.47e-05	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—CREBBP—prostate cancer	1.63e-06	1.47e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—MMP9—prostate cancer	1.63e-06	1.47e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—CDKN1A—prostate cancer	1.62e-06	1.46e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—PTEN—prostate cancer	1.62e-06	1.46e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—RXRA—prostate cancer	1.61e-06	1.46e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—MTHFR—prostate cancer	1.61e-06	1.46e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—CDKN1B—prostate cancer	1.6e-06	1.45e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—CYP1A1—prostate cancer	1.59e-06	1.44e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—PPARA—prostate cancer	1.58e-06	1.43e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—ERCC2—prostate cancer	1.58e-06	1.43e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—CYP1A1—prostate cancer	1.58e-06	1.42e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—prostate cancer	1.57e-06	1.42e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—ERCC2—prostate cancer	1.56e-06	1.41e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—IL6—prostate cancer	1.56e-06	1.41e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—COMT—prostate cancer	1.55e-06	1.4e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—NCOA2—prostate cancer	1.55e-06	1.4e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—NOS3—prostate cancer	1.55e-06	1.4e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—GSTP1—prostate cancer	1.55e-06	1.4e-05	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—PIK3CD—prostate cancer	1.54e-06	1.39e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—EP300—prostate cancer	1.54e-06	1.39e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—ITPR1—prostate cancer	1.52e-06	1.38e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—CTNNB1—prostate cancer	1.51e-06	1.37e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—SRC—prostate cancer	1.5e-06	1.35e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism of lipids and lipoproteins—EP300—prostate cancer	1.5e-06	1.35e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—CAV1—prostate cancer	1.49e-06	1.34e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—MTHFR—prostate cancer	1.48e-06	1.34e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—SLC5A5—prostate cancer	1.48e-06	1.34e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—CDKN1A—prostate cancer	1.48e-06	1.34e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—PTEN—prostate cancer	1.47e-06	1.33e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—MTHFR—prostate cancer	1.47e-06	1.33e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—VEGFA—prostate cancer	1.46e-06	1.32e-05	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—NOS3—prostate cancer	1.46e-06	1.32e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—PPARA—prostate cancer	1.45e-06	1.31e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—CYP2E1—prostate cancer	1.45e-06	1.31e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—STAT3—prostate cancer	1.45e-06	1.31e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—PPARA—prostate cancer	1.44e-06	1.3e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—AKT1—prostate cancer	1.44e-06	1.3e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—TYMS—prostate cancer	1.44e-06	1.3e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Gene Expression—AKT1—prostate cancer	1.43e-06	1.29e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—NQO1—prostate cancer	1.43e-06	1.29e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—PIK3CB—prostate cancer	1.43e-06	1.29e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—GSTM1—prostate cancer	1.42e-06	1.28e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	1.42e-06	1.28e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—TH—prostate cancer	1.41e-06	1.27e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—EP300—prostate cancer	1.41e-06	1.27e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—LPL—prostate cancer	1.39e-06	1.26e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—CYP1B1—prostate cancer	1.37e-06	1.24e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—CAV1—prostate cancer	1.37e-06	1.24e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—SRC—prostate cancer	1.37e-06	1.24e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—CAV1—prostate cancer	1.36e-06	1.23e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—PIK3CG—prostate cancer	1.35e-06	1.22e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—CYP1A1—prostate cancer	1.35e-06	1.22e-05	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—PIK3CB—prostate cancer	1.34e-06	1.22e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—MYC—prostate cancer	1.34e-06	1.21e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—TGFB1—prostate cancer	1.34e-06	1.21e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—ERCC2—prostate cancer	1.34e-06	1.21e-05	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—PTGS2—prostate cancer	1.33e-06	1.2e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—GGT1—prostate cancer	1.33e-06	1.2e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—STAT3—prostate cancer	1.32e-06	1.19e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—EGFR—prostate cancer	1.31e-06	1.19e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—NCOA1—prostate cancer	1.31e-06	1.18e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	1.29e-06	1.17e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—CYP19A1—prostate cancer	1.29e-06	1.17e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—INS—prostate cancer	1.28e-06	1.16e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—MTHFR—prostate cancer	1.26e-06	1.13e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—CREBBP—prostate cancer	1.26e-06	1.13e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—PIK3CG—prostate cancer	1.25e-06	1.13e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—RXRA—prostate cancer	1.24e-06	1.12e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—KRAS—prostate cancer	1.24e-06	1.12e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—PIK3CG—prostate cancer	1.23e-06	1.12e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—PTEN—prostate cancer	1.23e-06	1.12e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—PPARA—prostate cancer	1.23e-06	1.11e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—MYC—prostate cancer	1.22e-06	1.11e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—TGFB1—prostate cancer	1.22e-06	1.1e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—COMT—prostate cancer	1.2e-06	1.08e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—EGFR—prostate cancer	1.2e-06	1.08e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—GSTP1—prostate cancer	1.19e-06	1.08e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—PIK3CD—prostate cancer	1.19e-06	1.08e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—INS—prostate cancer	1.18e-06	1.07e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—EP300—prostate cancer	1.18e-06	1.06e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—ITPR1—prostate cancer	1.17e-06	1.06e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—INS—prostate cancer	1.17e-06	1.06e-05	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—PTEN—prostate cancer	1.16e-06	1.05e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—CAV1—prostate cancer	1.16e-06	1.05e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—CREBBP—prostate cancer	1.15e-06	1.04e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—CREBBP—prostate cancer	1.14e-06	1.03e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—PIK3CA—prostate cancer	1.14e-06	1.03e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—KRAS—prostate cancer	1.13e-06	1.02e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—NOS3—prostate cancer	1.12e-06	1.02e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—TYMS—prostate cancer	1.11e-06	1e-05	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—EP300—prostate cancer	1.11e-06	1e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	1.11e-06	1e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—TP53—prostate cancer	1.1e-06	9.97e-06	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—GSTM1—prostate cancer	1.1e-06	9.91e-06	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—PIK3CD—prostate cancer	1.09e-06	9.9e-06	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—PIK3CD—prostate cancer	1.09e-06	9.81e-06	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—LPL—prostate cancer	1.08e-06	9.73e-06	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—PIK3CG—prostate cancer	1.06e-06	9.54e-06	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—PIK3CA—prostate cancer	1.04e-06	9.4e-06	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—CYP1A1—prostate cancer	1.04e-06	9.4e-06	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—PIK3CB—prostate cancer	1.04e-06	9.38e-06	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—NOS3—prostate cancer	1.03e-06	9.34e-06	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—ERCC2—prostate cancer	1.03e-06	9.32e-06	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—PTGS2—prostate cancer	1.03e-06	9.29e-06	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—NOS3—prostate cancer	1.02e-06	9.26e-06	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—IL6—prostate cancer	1.01e-06	9.12e-06	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—INS—prostate cancer	9.99e-07	9.03e-06	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—CREBBP—prostate cancer	9.78e-07	8.84e-06	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—MTHFR—prostate cancer	9.69e-07	8.76e-06	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—PIK3CB—prostate cancer	9.54e-07	8.63e-06	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—PPARA—prostate cancer	9.51e-07	8.59e-06	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—PIK3CB—prostate cancer	9.46e-07	8.55e-06	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—PTGS2—prostate cancer	9.46e-07	8.55e-06	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—PTGS2—prostate cancer	9.37e-07	8.47e-06	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—AKT1—prostate cancer	9.31e-07	8.42e-06	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—PIK3CD—prostate cancer	9.27e-07	8.38e-06	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—IL6—prostate cancer	9.21e-07	8.32e-06	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—PTEN—prostate cancer	8.97e-07	8.1e-06	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—CAV1—prostate cancer	8.94e-07	8.08e-06	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—NOS3—prostate cancer	8.76e-07	7.92e-06	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—PIK3CA—prostate cancer	8.71e-07	7.87e-06	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—EP300—prostate cancer	8.55e-07	7.73e-06	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—AKT1—prostate cancer	8.49e-07	7.68e-06	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—PTEN—prostate cancer	8.25e-07	7.45e-06	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—PIK3CA—prostate cancer	8.2e-07	7.41e-06	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—PTEN—prostate cancer	8.17e-07	7.39e-06	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—PIK3CG—prostate cancer	8.14e-07	7.36e-06	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—PIK3CB—prostate cancer	8.08e-07	7.31e-06	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—PTGS2—prostate cancer	8.01e-07	7.24e-06	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—EP300—prostate cancer	7.86e-07	7.11e-06	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—EP300—prostate cancer	7.8e-07	7.05e-06	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—INS—prostate cancer	7.71e-07	6.97e-06	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—CREBBP—prostate cancer	7.55e-07	6.82e-06	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—PIK3CD—prostate cancer	7.16e-07	6.47e-06	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—AKT1—prostate cancer	7.11e-07	6.43e-06	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—PTEN—prostate cancer	6.99e-07	6.31e-06	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—NOS3—prostate cancer	6.76e-07	6.11e-06	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—AKT1—prostate cancer	6.7e-07	6.05e-06	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—EP300—prostate cancer	6.66e-07	6.02e-06	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—PIK3CA—prostate cancer	6.32e-07	5.72e-06	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—PIK3CB—prostate cancer	6.24e-07	5.64e-06	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—PTGS2—prostate cancer	6.18e-07	5.59e-06	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—PIK3CA—prostate cancer	5.82e-07	5.26e-06	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—PIK3CA—prostate cancer	5.77e-07	5.21e-06	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—PTEN—prostate cancer	5.39e-07	4.87e-06	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—AKT1—prostate cancer	5.17e-07	4.67e-06	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—EP300—prostate cancer	5.14e-07	4.65e-06	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—PIK3CA—prostate cancer	4.93e-07	4.45e-06	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—AKT1—prostate cancer	4.75e-07	4.3e-06	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—AKT1—prostate cancer	4.71e-07	4.26e-06	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—AKT1—prostate cancer	4.03e-07	3.64e-06	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—PIK3CA—prostate cancer	3.8e-07	3.44e-06	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—AKT1—prostate cancer	3.11e-07	2.81e-06	CbGpPWpGaD
